# PVSRIPO in Combination With Nivolumab in Melanoma

> **NCT04125719** · PHASE1 · WITHDRAWN · sponsor: **Darell Bigner**

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** PVSRIPO
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04125719
- **Lead sponsor:** Darell Bigner
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-06-01
- **Primary completion:** 2024-10-01
- **Final completion:** 2024-10-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** resubmission planned
- **Last updated:** 2020-02-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04125719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04125719, "PVSRIPO in Combination With Nivolumab in Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04125719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*